OncoMatch/Clinical Trials/NCT06657144
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Is NCT06657144 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CHS-114 and Toripalimab for metastatic solid tumor.
Treatment: CHS-114 · Toripalimab · 5 Fluorouracil · Cisplatin — The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) negative
HER2-negative
Required: MMR proficient mismatch repair
microsatellite stable (MSS)/proficient mismatch repair (pMMR)
Required: MSI microsatellite stable
microsatellite stable (MSS)/proficient mismatch repair (pMMR)
Required: PD-L1 (CD274) expression (IHC assay score required; no threshold specified)
Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests
Required: RAS status documented
RAS...status for each participant must be documented
Required: BRAF status documented
BRAF...status for each participant must be documented
Required: MSI status documented
microsatellite instability/mismatch repair status for each participant must be documented
Required: MMR status documented
microsatellite instability/mismatch repair status for each participant must be documented
Disease stage
Required: Stage III, IV
Metastatic disease required
unresectable, locally advanced or metastatic...at least 1 measurable lesion based on RECIST v1.1
Prior therapy
Must have received: platinum-based chemotherapy — first line
Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet
Must have received: fluoropyrimidine — first line
Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet
Must have received: platinum-based chemotherapy — first line
Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel
Must have received: taxane (paclitaxel) — first line
Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel
Cannot have received: systemic anticancer therapy
Received 2 prior systemic anticancer therapies for advanced or metastatic disease
Cannot have received: systemic anticancer therapy
Received 1 prior systemic anticancer therapies for advanced or metastatic disease
Cannot have received: anti-C-C motif chemokine receptor 8 (CCR8) antibody
Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody
Lab requirements
Kidney function
Calculated creatinine clearance 60 mL/min
Calculated creatinine clearance 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Arizona Cancer Center · Tucson, Arizona
- City of Hope · Duarte, California
- University of Colorado - Aurora Cancer Center · Aurora, Colorado
- Winship Cancer Center - Emory University · Atlanta, Georgia
- Ochsner Health · New Orleans, Louisiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify